Atomoxetine is a medication that works by increasing the levels of norepinephrine (a natural chemical) in the brain. It is typically used to treat attention deficit hyperactivity disorder (ADHD), but in this trial, it is being studied for its potential to help reduce freezing of gait (a movement problem where people temporarily feel stuck while walking) in people with Parkinson’s disease. The medication works by affecting the noradrenergic system, which is involved in arousal and attention.

Parkinson’s disease – A progressive neurological disorder that affects movement and motor control. The condition develops when nerve cells in a specific part of the brain begin to break down and die, leading to decreased production of dopamine. The disease typically starts gradually with mild symptoms that worsen over time, including tremors, stiffness, and balance problems. People with Parkinson’s may experience slowed movement (bradykinesia), rigid muscles, impaired posture, and changes in speech. The condition can also cause freezing of gait (FOG), where patients temporarily feel as if their feet are glued to the ground during walking.